A Houston entrepreneur and investor is bullish on bringing flying motorcycles to existence. Courtesy of Aviator Cycles

When it comes to flying cars, Jeff Chimenti wants to give Elon Musk a run for his money — even though Musk, famously, has a lot of that.

But Chimenti is confident that his startup, Aviator Cycles, might be one of the first to get a vehicle off the ground and up into consumer markets. That's because he's not focusing on cars at all — the prototype, unveiled at a recent promotional event in the Woodlands, is a critical propulsion system for what Chimenti calls a personal air vehicle, or PAV.

The PAVs that Aviator Cycles plans to make are more like motorcycles or four-wheelers and intended for recreational use — but the high-tech system could change how other designers make flying vehicles.

"All of this is really happening," says Chimenti, a Houston-based investor and chief visionary officer and co-founder for the startup. "We're pushing it forward."

And, hopefully, upward. Aviator Cycles's first PAV doesn't fly yet, but smaller models have, and Chimenti expects to see a successful launch within one year. The company is making PAVs because there's a lot of red tape around making cars — traffic systems will need to be redrafted.

So for now, the unique propulsion system, which has come a long way since co-founder Jesse Marcel made his first patent on it before the company was even made, is being fastened to the Aerorunner GSX, a sports vehicle that will flutter from about four feet off the ground for safety.

Aviator Cycles plans to start taking reservations for these in the next six months. But Marcel says that his proprietary propulsion system will eventually make its way to other companies and vehicles; Audi, Porsche and Boeing, for example, have announced flying car projects in recent years.

All this innovation is part of a push toward alternative transportation, but it feels like a resurgent space race — just a little lower this time. Aviator Cycles, based in Spokane, Washington, isn't the only manufacturer. In 2018, California-based Hoversurf announced a hoverbike with a set of helicopter blades. It was supposed to ship out earlier this year for $150,000. Across the world — in Britain and Israel, for example — companies are developing bikes to compete in a brand-new flying vehicle market.

"Everybody that designs is great, but they're ultimately going to have to use our propulsion system," says Chimenti.

A new kind of 4x4 might fly, literally, in the Pacific Northwest, where the culture is all hiking and being outside. Texans, though, tend to have a better relationship with their air-conditioners than the great outdoors. Houston, especially, is mostly the urban sprawl of twisting highways — the same unregulatable stretch of concrete that Chimenti has avoided making vehicles for.

But Chimenti is optimistic about the potential for Space City. Last October, the Houston City Council gave $18.8 million to develop the Houston Spaceport, a kind of "mission control" for the future of commercial alternative transportation. Near Ellington Airport, the site has launch pads and lab space — but, maybe most excitingly for people like Chimenti, it has a tech incubator for developers to design and test their equipment.

Houston, then, has a historical stake in how we explore the space above our heads — and what's left for the regular person to explore is closer, below the stratosphere. If Houston has already been instrumental in getting all the way up there, then some light hovering will be nothing. When it comes to flying motocross, Chimenti says, Houston won't have a problem.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.